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Abstract
Hepatocellular carcinoma (HCC) is responsible for a large proportion of cancer deaths worldwide. HCC is frequently
diagnosed after the development of clinical deterioration at which time survival is measured in months. Long-term survival
requires detection of small tumors, often present in asymptomatic individuals, which may be more amenable to invasive
therapeutic options. Surveillance of high-risk individuals for HCC is commonly performed using the serum marker alfa-
fetoprotein (AFP) often in combination with ultrasonography. Various other serologic markers are currently being tested to
help improve surveillance accuracy. Diagnosis of HCC often requires more sophisticated imaging modalities such as CT scan
and MRI, which have multiphasic contrast enhancement capabilities. Serum AFP used alone can be helpful if levels
are markedly elevated, which occurs in fewer than half of cases at time of diagnosis. Confirmation by liver biopsy can be
performed under circumstances when the diagnosis of HCC remains unclear.
Introduction
Each year 500 000 to 1 million individuals are
diagnosed with hepatocellular carcinoma (HCC)
worldwide [1]. Incidence rates demonstrate dramatic
geographic variability, ranging from55 new cases per
100 000 persons per year in developed western coun-
tries to4100 per 100 000 persons per year in parts of
south-east Asia and sub-Saharan Africa [2]. Although
the United States is among regions of low incidence, a
70% increase in HCC has been observed over the past
two decades, apparently related to the emergence of
chronic hepatitis C [3]. The life expectancy of patients
with HCC is poor, with a mean survival of 6–20
months and likely reflects the mortality/incidence ratio,
which is close to 1 [4,5]. These figures have remained
steady despite substantial progress in the diagnostic
and therapeutic arena of HCC.
Removal of HCC by surgical means offers the best
chance for possible cure. Criteria for such intervention
have been refined over the last decade to optimize
long-term survival in selected patients. Unfortunately
520% of patients meet the criteria for resection at time
of diagnosis [6]. The focus of much research revolves
around diagnostic strategies to identify early HCC,
defined by size of tumor and number of lesions.
Diagnostic tools commonly used include the serum
tumor marker alfa-fetoprotein (AFP), radiographic
imaging, and liver biopsy. No universal guidelines for
diagnosis exist, partly as a result of marked differences
in the diagnostic approach between Eastern and
Western institutions [7]; however, common themes do
emerge which allow for important distinctions and
conclusions to be made.
Surveillance for HCC
Identification of early HCC which is potentially
amenable to aggressive intervention and improved
survival is the rationale behind screening for HCC. An
effective screening program, however, requires certain
criteria to be successful, including the following: a
common disease with substantial mortality, an identi-
fiable target group, acceptable tests with high sensi-
tivity and specificity, and available treatment [8].
Surveillance of individuals at risk for HCC has
been a matter of controversy for decades. Geographic
variations in target populations, screening tools, and
therapy complicate assessment of international litera-
ture on the effectiveness of surveillance for HCC.
Many studies are limited by lead time bias. To date no
substantial evidence has accumulated which improves
survival benefit with surveillance of high-risk patients.
As a result no universally accepted guidelines are
currently available. Several large studies on surveil-
lance do suggest benefits, however, in identifying
smaller tumors with subsequent improved survival
[9–11]. Bolondi et al. demonstrated a median survival
of 30 months in patients whose HCC was detected by
surveillance versus 15 months in those discovered by
chance [12]. Other studies have been less convincing
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[13]. Regardless, it has become common practice
among hepatologists to apply one of several surveil-
lance methods to their high-risk patients [14].
Surveillance intervals for HCC are based on a
balance between the tumor doubling time and the cost
of the screening tests. Doubling time of HCC ranges
from 1 to 19 months with a median of 4–6 months
[15]. Most study protocols conduct screening every 6
months. The overall cost of surveillance for HCC
varies according to region, population incidence, and
the screening tools used. The cost of finding each
tumor in high-risk individuals ranges from $11 000 to
$25 000 [16]. The cost per life saved is between $2600
and $112 996. This can be compared with screening
colonoscopy for colon cancer where the cost per life
year saved is $25 000 and is deemed acceptable [17].
Target population for surveillance
The key to successful surveillance of HCC is defining
the high-risk patient. Older age, male gender, family
history of HCC, and underlying cirrhosis are
repeatedly demonstrated risks factors regardless of
geographic region. Hepatitis B is the most common
cause of HCC in regions of high incidence [18,19]. In
Taiwan, 70–90% of HCC patients are hepatitis B virus
surface antigen (HBsAg)-positive compared with
525% in the United States [20]. In the Far East, many
individuals are carriers of HBV, presumably because of
the frequency of vertical transmission. As a result HCC
tends to develop approximately one to two decades
earlier than in regions of low incidence, where trans-
mission of HBV is primarily via sexual and parenteral
routes [21]. Chronic hepatitis B carriers have a 5–15-
fold increased risk for HCC compared with the general
population, which rises with HB e antigen positivity
and cirrhosis [22,23]. Prevention of hepatitis B with
universal vaccination in children has been proven to
significantly reduce the incidence of HCC [24].
HCV RNA is found in the large majority of HCC
patients in Japan and Spain and is on the rise in the
United States. In contrast to HBV, hepatitis C virus
(HCV) does not integrate into the host genome, yet
chronic disease does incur a risk of developing HCC up
to 24 times that of the general population [25,26].
Genotype 1b has been linked to greater risk than other
genotypes, although all genotypes have been impli-
cated in HCC [27]. Cirrhosis invariably precedes the
development of HCC. In the USA, once cirrhosis due
to hepatitis C is established, 1–4% of patients will
develop HCC annually [28]. HCC has been shown
to develop earlier and more frequently with HBV co-
infection or alcohol abuse [25,29].
Cirrhosis from any cause can pose an increased risk
for HCC at various levels of magnitude. Hereditary
hemochromatosis carries a risk of up to 200-fold
compared with the general population [30]. Cirrhosis
associated with viral hepatitis generally leads to HCC
more readily than non-viral-induced cirrhosis [31–33].
Primary biliary cirrhosis, autoimmune hepatitis, and
Wilson disease carry less risk [34,35]. Cirrhosis, how-
ever, is not a prerequisite for HCC. As many as 30% of
chronic hepatitis B patients who develop HCC are
non-cirrhotic. In one study from France, 25% of
patients who underwent surgical resection of HCC had
either minimal or no cirrhosis [36].
Screening tests
AFP is a serum glycoprotein that was first recognized as
a marker for HCC more than 40 years ago and has
since been described to detect preclinical HCC. The
fetal yolk sac and fetal liver generate high levels of AFP,
which decline to 510 ng/dl within 300 days of birth
[37]. Serum elevations thereafter suggest underlying
pathology which may be malignant. Any tumor arising
from organs derived from the same endodermal lining
as the hepatic diverticulum can be associated with
elevations in serum AFP levels, including cancers of
the stomach, pancreas, and biliary tree. Pregnancy and
nonseminomatous germ-cell tumors must also be
considered. Chronic hepatitis or cirrhosis raise AFP in
20% and 40% of patients, respectively, and tend to
fluctuate in parallel with underlying inflammatory
activity [38].
HCC can produce a range of AFP values from
normal to 4100 000 ng/ml [15]. Normal AFP levels
are present in as many as 30% of patients at time of
diagnosis and usually remain low, even with advanced
HCC [39]. AFP4400–500 ng/ml is considered diag-
nostic for HCC, although fewer than half of patients
may generate levels that high [39]. With values of
that magnitude, the specificity of AFP is close to 100%
but at a cost to the sensitivity which falls below 45%
[40]. In a study using 20 ng/ml as the cut-off point,
the sensitivity rose to 78.9%, although the specificity
declined to 78.1% [41]. The positive predictive
value (PPV) of AFP is low, ranging from 9% to 32%
[42]. McMahon et al. demonstrated survival benefits
in a large study using AFP alone for surveillance of
HCC in chronic hepatitis B patients [9]. However,
this is not considered common practice in light of
the poor accuracy demonstrated in subsequent studies
and in different populations [43].
Attempts to improve the accuracy of AFP have
centered around the investigation of isoforms which
may be specific for HCC. Human AFP is a 70-kd
glycoprotein consisting of 591 amino acids and a
terminal sugar side chain. Up to 11 AFP isoforms
exist based on variations in the glycan terminal chain
[44,45]. Microheterogenity of isoforms has been
successfully identified using lectin electrophoretic
techniques. Lectins are human or animal proteins
that bind specifically to particular sugars. AFP specific
for HCC has been shown to bind lectins lens
culinaris agglutinin-A (AFP-L3), concanavalin A, and
erythroagglutinating phytohemagglutinin (E-PHA)
[46–48]. Taketa et al. found AFP-L3 to be positive in
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about 35% of patients with HCC smaller than 2 cm,
which may be present in serum up to 9 months before
detection by imaging techniques [48]. More recently,
isoelectric focusing has been investigated, which frac-
tionates AFP into four variant bands, I–IV. AFP bands
III and IV can be specific for HCC and help differ-
entiate from AFP of cirrhosis or pregnancy [49]. One
study showed a positive predictive value of 73.1% for
identifying HCC using AFP band II compared with
41.5% using conventional AFP [50]. Although these
techniques potentially demonstrate improved specifi-
city for HCC, its routine use in clinical practice is
restricted by high cost and assay complexity.
Des-gamma-carboxy prothombin (DCP), also
called PIVKA II (protein induced by vitamin K
absence), is a widely used tumor marker in Japan that
was first described by Liebman et al. in 1984 as an
abnormal form of prothombin highly specific for HCC
[51]. No prospective studies have been done to follow a
surveillance cohort. In western patients, specificity was
described as high as 95% in one study; however, other
studies have shown poor sensitivity in tumors53 cm,
which limits its clinical use [52–54]. Recent studies
suggest that DCP values may be a prognostic indicator
in patients with HCC [55].
Ultrasound (US) imaging is commonly applied in
addition to, or in place of, AFP to help detect
small hepatic tumors 53 cm. Its widespread use as a
surveillance tool relates to its noninvasive nature, high
availability, and low cost. In combination with AFP the
PPV can be as high as 94% [43]. However, limitations
exist with operator experience and when imaging obese
or cirrhotic individuals. The sensitivity and positive
predictive value can be as low as 35% and 15%,
respectively, in some cases with cirrhosis [13,56,57].
HCC lesions typically are hypoechoic relative to
surrounding tissue when under 3 cm. Larger lesions
are generally hyperechoic with an infiltrative or mosaic
pattern which may be surrounded by a thin hypoechoic
fibrous capsule. Variation in sonographic appearance
exists as a result of the presence of fat, calcium, and
necrosis. CT imaging has not been well studied in the
context of surveillance testing and is more commonly
applied for further diagnostic purposes. A study on
hepatitis C cirrhotics demonstrated CT scan imaging
to have a higher sensitivity for detecting HCC than
either US or AFP when used alone (88% vs 59% and
62%, respectively) [58]. Less availability and high cost
limit the use of CT; however, up to 25% of hepato-
logists in the United States have been shown to use it
on their high-risk patients in a recent survey [14]. Few
data exist as regards magnetic resonance imaging
(MRI) as a surveillance tool for HCC.
Diagnostic evaluation of HCC
Clinical presentation
HCC classically arises and grows in silent fashion, mak-
ing its discovery challenging prior to the development
of later stage disease. The various clinical presentations
generally relate to the extent of hepatic reserve at time
of diagnosis. Cirrhotic patients tend to have less
tolerance for malignant infiltration within the liver and
frequently present with nonspecific signs and symp-
toms of hepatic decompensation such as jaundice,
hepatic encephalopathy, and anasarca. Ascites, vari-
ceal bleeding or other findings consistent with portal
hypertension may indicate malignant invasion of HCC
into portal structures. Abnormal laboratory values
are nonspecific for chronic liver disease and may re-
flect effects of commonly prescribed medications
for cirrhotics such as spironolactone. Noncirrhotic
patients with HCC typically present in a different
manner, as is commonly seen in sub-Saharan Africa
and other high incidence areas. Their tumors are often
allowed to grow with much less restriction. Symptoms
are often related to long-standing malignancy and
tumor growth including malaise, anorexia, wasting,
right upper quadrant abdominal pain, and distension
[4]. Physical examination may reveal an abdominal
mass or hepatomegaly with hard and irregular borders
that may demonstrate a vascular bruit [59]. Painless
obstructive jaundice can indicate tumor encroachment
onto adjacent extrahepatic biliary structures [60]. A
rare catastrophic complication of HCC is tumor
rupture which occurs when a large vascular tumor on
the periphery of the liver outgrows its blood supply
[61]. These patients present with sudden severe ab-
dominal pain, peritoneal irritation, and hypotension.
Peritoneal lavage or abdominal laparotomy can
confirm the diagnosis. It is important to note that these
findings and complications are not strictly confined to
any patient scenario and considerable overlap does
exist.
Extrahepatic manifestations of HCC are well
described and may relate either to distant metastases
or paraneoplastic phenomena. Advanced HCC can
metastasize to any organ system via hematogenous or
lymphatic routes, and most commonly spreads to
bone, lung, and abdominal viscera [62]. Bone pain or
other complications relating to metastasis may be the
initial presenting sign of HCC. Paraneoplastic mani-
festations occur rarely in HCC and include hypogly-
cemia, hypocalcemia, polycythemia, and feminization
syndrome [63]. Watery diarrhea has been shown to be
significantly more common with cirrhosis and HCC
than with cirrhosis alone and can be an initial pre-
senting symptom. Increased production of intestinal
secretory substances, such as gastrin and vasoactive
intestinal peptide (VIP), has been suggested as a
possible cause [64,65]. Various cutaneous features are
well described in HCC including the Leser-Trelat sign,
dermatomyositis, pemphigus foliaceus, and pityriasis
rotunda, but are not necessarily specific for the disease
[66]. Porphyria cutanea tarda (PCT) is frequently
associated with chronic hepatitis C. Several studies
have linked its presentation to a higher risk of devel-
oping HCC [67].
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Routine surveillance of high-risk patients has made
the discovery of asymptomatic HCC more common.
These individuals whose tumors are identified prior to
the development of hepatic decompensation or other
complications described above, are more likely to be
better candidates for aggressive interventions proven to
prolong survival.
AFP in diagnosis of HCC
AFP has been shown to correlate with tumor size and
volume at time of diagnosis. A study from Thailand
found that HCC patients with AFP 4400 ng/ml
tend to have greater size, bilobar involvement, portal
vein thrombosis, and decreased survival [68]. When
left untreated, AFP-producing tumors continue to
increase over time, coinciding with progression of
disease. Poorly differentiated tumors with more
aggressive features can be seen more often in patients
with high levels of AFP. Prognosis has been shown
to be reduced when AFP levels are41000 ng/ml, but
exceptions do exist [69]. Tumors with normal AFP
levels at time of diagnosis tend to remain so throughout
their course even with advanced disease. In-
consistencies in tumor AFP levels reflect variables
associated with its synthesis in HCC and pose a
challenge in making systematic assumptions on tumor
characteristics based on AFP level alone.
Monitoring AFP levels can be helpful in the diag-
nosis of recurrent disease, although this is largely
restricted to patients with AFP-producing tumors.
Successful removal of tumor by surgical means is
usually followed by an immediate fall in AFP levels to
normal values, as the half-life is 3.4–5 days [38].
Persistently elevated levels may indicate residual
disease or incomplete resection, yet exceptions have
been noted. Similarly, normalized AFP levels do not
exclude the possibility of remaining disease [70–72].
A gradual rise in AFP is frequently consistent with
disease recurrence. AFP levels are also shown to mirror
tumor responsiveness to nonsurgical therapies for HCC
such as chemotherapy [73]. In one study, patients
whose AFP remained low in response to chemotherapy
had a survival advantage compared with those with
either transient AFP fall or no response at all [74].
Diagnostic imaging
Imaging plays a key role in the diagnosis of HCC.
Advances in imaging technology over the past
two decades have contributed to better characteriza-
tion of hepatic lesions with a wider array of options.
Regardless, detection of small tumors continues to be
difficult, particularly in cirrhotic individuals whose
parenchymal architecture is abnormal. Differentiating
HCC from benign lesions commonly seen in
cirrhosis or from secondary malignancies remains a
challenge.
Ultrasound
Ultrasound (US) imaging has largely been replaced in
diagnosis by CT scan and MRI as a diagnostic instru-
ment of choice as a result of low sensitivity and positive
predictive value with coexisting cirrhosis. The recent
addition of sonographic contrast agents such as intra-
arterial carbon dioxide and helium shows promise in
improving accuracy [75–77]. However, application of
duplex and color Doppler sonography can be particu-
larly useful in the assessment of intrahepatic vascular
flow. HCC lesions typically display fine branching
patterns of increased vascularity with greater flow
velocity than metastatic lesions or hemangiomas
[78,79]. Doppler evaluation of the portal vein can help
differentiate bland thrombus from tumor invasion.
Malignant portal invasion commonly produces wave
forms demonstrating arterial flow. The power Doppler
is thought to be three to five times more sensitive in
depicting tumor vascularity than color Doppler by
eliminating angle dependence [80–82].
CT scan
CT evaluation of patients with suspected HCC should
be done using multiphasic contrast imaging of the
liver. Following rapid intravenous infusion of con-
trast, imaging is conducted at various time intervals
corresponding to the phase of contrast enhancement.
Triphasic scanning denotes hepatic imaging performed
before contrast, during arterial and venous phases.
HCC tumors derive blood flow predominantly from
the hepatic artery and tend to enhance during the
arterial phase or 2–40 seconds after contrast infusion.
The surrounding hepatic parenchyma obtains 75–80%
of its blood flow through the portal vein and is best
demonstrated 50–90 seconds after infusion of contrast
during the portal phase. Arterial phase enhancement
can increase HCC tumor detection by 10% [83,84].
HCC typically appears heterogeneous on CT, which
may reflect intratumoral fibrous stranding (mosaic
sign), fatty metamorphosis, necrosis, or calcifications
[85,86]. The presence of satellite nodules in close
proximity to the lesion is often characteristic. Fibrous
structures within or encapsulating the lesion strongly
retain contrast and enhance readily on delayed imaging
(3–10 min after infusion) [87].
Brancatelli et al. describe hepatic lesions which can
mimic HCC on CT imaging including regenerating
nodules, hemangiomas, focal fat, dysplastic nodules,
and peliosis [88]. The accuracy increases with greater
imaging speed, which allows faster administration
of contrast media, thereby dramatically improving
contrast enhancement [89]. The added speed and
flexibility of multidetector CT (MDCT) allows high
quality, thin-section imaging with three-dimensional
capabilities [90]. CT arteriography is a more invasive
yet effective option to improve accuracy as a result of
higher quantity of contrast administered at a faster rate.
In a large population-based study, Oliver et al. reported
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a 66% increase in detection of HCC foci compared
with triphasic CT scanning [91]. However, the invasive
and costly nature of this approach tends to restrict its
use. CT arteriography and portography appear to be
used more often in the Far East to define hepatic
vasculature before surgical intervention.
MRI
MRI uses similar concepts to those applied to CT
imaging when evaluating hepatic lesions suspicious
for HCC. Recent advances in MR technology allow
images to be obtained within the time frame of one
breath hold. T1- and T2-weighted sequence images of
HCC lesions vary considerably but typically appear
hypointense and hyperintense, respectively. Focal
hemorrhage, fatty change, or tumor accumulation of
copper and glycogen contribute to this inconsistency.
MRI sensitivity is lowest when evaluating tumors
52 cm in diameter [92]. Dynamic gadolinium contrast
imaging enhances arterial blood supply during the early
phase, which improves characterization of HCC
tumors. The sensitivity and specificity are similar to
those of multiphasic CT scan imaging. The addition of
superparamagnetic iron oxide contrast has been
investigated to improve accuracy, particularly with T2-
weighted sequencing [89,93]. Superparamagnetic iron
oxide comprises tissue-specific MRI contrast agent
particles taken up by Kupffer cells in the liver.
The combination of superparamagnetic iron oxide-
enhanced and gadolinium chelate-enhanced dynamic
MRI produces results comparable to those of CT
hepatic arteriography [94]. MRI has become the
diagnostic imaging mode of choice for HCC at many
institutions worldwide.
Angiography
Angiography has been used as a diagnostic tool for
HCC because of its highly vascular nature; however,
the detection of tumors has been disappointing, par-
ticularly when 52 cm in diameter. At present angi-
ography is more often used to define hepatic anatomy
before resection or as guidance for transarterial
chemoembolization therapy.
Evaluation for extrahepatic spread
Radiographic imaging for extrahepatic metastasis is
routinely performed on patients with early disease in
order to confirm proper staging prior to surgical
intervention. No guidelines exist and protocols differ
among centers and regions. At our institution, patients
undergo CT scan of the chest, abdomen, and pelvis;
nuclear bone scan; and positron emission tomography
(PET). Patients who qualify for nonsurgical
procedures (transarterial chemoembolization, radio-
frequency ablation, chemotherapy) may benefit from
further imaging which may potentially spare patients
from unnecessary intervention. With more advanced
stage HCC, full body imaging may not be necessary
unless there is clinical suspicion of spread.
PET scan has limited use as a diagnostic tool for
HCC. PET nuclear imaging relies on radiolabeled
glucose (F-18 FDG), which incorporates into neo-
plastic cells demonstrating increased metabolic activity.
Well or moderately differentiated HCC tumors that
metastasize may not generate a high level of metabo-
lism requirements compared to that of surrounding
tissues. A recent study by Liangpunsakul et al. showed
that PET did not reveal abnormal hepatic lesions
which were identified on CT scan and later proven
HCC on explant [95]. The high cost of PET also limits
its frequent use.
Liver biopsy
Diagnostic evaluation of hepatic lesions with liver
biopsy has been practiced for over half a century. When
performed at specialized centers, liver biopsy offers a
safe and effective means to confirm suspicious lesions
for HCC. Cytologic and histologic samples can be
obtained by percutaneous fine-needle aspiration
(FNA) and needle core biopsy, respectively, under US
or CT guidance. The diagnostic accuracy of liver
biopsy is greater when both FNA and core biopsy
techniques are used simultaneously than when either
is used alone. The sensitivity and specificity are
superior to any other diagnostic test, at 96% and 95%,
respectively [96]. An on-site pathologist can provide
immediate interpretations of cytologic cell blocks to
assure proper placement of the biopsy needle. Open
surgical biopsy procedures may sometimes be
performed when suspected HCC lesions cannot be
accurately located by radiographic methods.
Microscopic features of HCC include elevated
nuclear to cytoplasmic ratio, trabecular architecture,
atypical naked nuclei, and peripheral endothelial
wrapping [97]. Histologic appearance ranges from
nearly normal-appearing hepatocytes in well differ-
entiated tumors to the largely anaplastic multinucleate
giant cells characteristic of poorly differentiated HCC
[98]. Distinguishing well differentiated HCC from
benign hepatic masses such as adenoma or focal
nodular hyperplasia may be difficult. The most recog-
nizable premalignant histological finding is dysplasia.
Liver biopsy need not be performed under circum-
stances in which the diagnosis of HCC is certain after
clinical, laboratory, and radiographic evaluation.
Confirmation of HCC with liver biopsy plays a larger
role in various other emerging scenarios. One such
scenario is prior to orthotopic liver transplantation or
hepatic resection. Routine surveillance programs are
more frequently identifying tumors in younger
asymptomatic patients with smaller lesions and better
hepatic reserve. Many of these patients are eligible for
surgical interventions which can significantly improve
survival [99]. Without preoperative confirmation of
HCC by liver biopsy several studies have shown that
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the rate of false-positive diagnosis can be substantial in
patients with small tumors [76,100,101]. In the United
States, the number of HCC patients transplanted has
increased substantially over the past decade, particu-
larly with the implementation of the MELD transplant
allocation system. Hayashi et al. recently demonstrated
that the false-positive rate can be as high as 33% after
histological examination of the explant [102]. This risk
of subjecting patients with small hepatic lesions to
unnecessary surgical intervention can be limited by
performing liver biopsy. The accuracy of liver biopsy in
diagnosing lesions52 cm in diameter is 95.6% [103].
Complications associated with liver biopsy are rare and
can be diminished by using a one stick approach, such
as the coaxial technique. Mortality rates are between
0.006% and 0.3%, with risk of serious hemorrhage or
infection 51% [104]. Liver biopsy should be avoided
when platelet counts are 550 000 per mm3 or the
international normalizing ratio (INR) is42.
The potential for spread of tumor from the biopsy
needle track is of great concern and fuels much of the
controversy surrounding the need for liver biopsy.
Although several studies show rates as high as 5%, the
majority of large studies indicate that the risk is closer
to 1% [105–108]. At our institution, not one case has
been identified after a recent review of all liver biopsies
done over a 5-year period. Furthermore, follow-up
studies of cases in which needle tract metastasis
were excised indicate that the long-term survival of
transplant or resected patients was not affected
[106,109,110].
Another common scenario in which the liver biopsy
can be useful is in the patient whose suspicious lesion
does not necessarily meet the characteristic radio-
graphic or laboratory features of HCC. For example,
the patient with an AFP 5400 ng/ml with a lesion
which fully demonstrates arterial enhancement on
multiphasic CT imaging. AFP 5400 ng/ml can be
present in as many as 60% of patients at presentation,
while HCC tumor with fatty change or necrosis can
impede characteristic radiographic arterial enhance-
ment. Many patients fit this “gray zone” and confir-
mation of the diagnosis is important, especially as
some will go on to have interventions such as radio-
frequency ablation, transarterial chemoembolization,
or chemotherapy.
Summary
The diagnosis of HCC poses many challenges which
can vary among different regions and centers. AFP and
US imaging are most often used every 6 months for
surveillance purposes in high-risk individuals. In the
presence of a rising AFP or suspicion of underlying
malignancy, surveillance intervals should be shortened
and more sensitive imaging techniques such as multi-
phasic CT scan or MRI can be applied. The intensity
of diagnostic work-up should be individualized and
tailored according to each patient’s potential to tolerate
aggressive therapeutic interventions. Liver biopsy can
confirm diagnosis when necessary or rule out other
lesions that may mimic HCC. Several diagnostic stra-
tegies have been proposed, many of which are center-
and region-specific. The European Association for the
Study of the Liver (EASL), for example, has listed
standard criteria for diagnosis of HCC that incorporate
both invasive and noninvasive measures [111]. Non-
invasive criteria include two imaging techniques, both
demonstrating a focal lesion 42 cm in diameter with
features of arterial hypervascularization, or a single
radiologic study with these features combined with a
serum AFP level of4400 ng/ml. Use of this and other
criteria can be very helpful, but the lack of evidence-
based studies should preclude their strict use in diag-
nosis of HCC. Further research studies continue to
focus on developing ways to improve diagnostic tools
and strategies with the aim of identifying earlier stages
of HCC.
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